Role of MetMAb (OA-5D5) in c-MET active lung malignancies

Expert Opinion on Biological Therapy

Volumn 11, Issue 12, 2011, Pages 1655-1662

  Surati, Mosmi ^a   Patel, Premal ^b   Peterson, Amy ^b   Salgia, Ravi ^a  

^a UNIVERSITY OF CHICAGO   (United States)

^b GENENTECH INC   (United States)

Author keywords

c MET; HGF; MetMAb; monoclonal antibody; non small cell lung cancer; personalized medicine; targeted therapy

Indexed keywords

ERLOTINIB; METMAB; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY DN30; MONOCLONAL ANTIBODY L2G7; PLACEBO; RILOTUMUMAB; SCATTER FACTOR; SCATTER FACTOR RECEPTOR; UNCLASSIFIED DRUG;

AREA UNDER THE CURVE; CANCER CHEMOTHERAPY; DRUG TOLERABILITY; LUNG CANCER; LUNG NON SMALL CELL CANCER; MONOTHERAPY; NONHUMAN; OVERALL SURVIVAL; REVIEW; SINGLE DRUG DOSE;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; HEPATOCYTE GROWTH FACTOR; HUMANS; LIGANDS; LUNG NEOPLASMS; PROTO-ONCOGENE PROTEINS C-MET; TREATMENT OUTCOME;

EID: 80555135913     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.2011.626762     Document Type: Review

References (46)

1. Schilsky RL. Personalized medicine in oncology: the future is now. Nat Rev Drug Discov 2010;9:363-6
2. Liotta LA, Kohn EC, Petricoin EF. Clinical proteomics: personalized molecular medicine. JAMA 2001;286:2211-14
3. Maertens T, Nils-Ole S, Eckerich C, et al. A novel one-armed anti-c-met antibody inhibits glioblastoma growth in vivo. Clin Cancer Res 2006;12:6144-52
4. Altekruse SF, Kosary CL, Krapcho M, et al. SEER Cancer Statistics Review, 1975-2007, Bethesda, MD National Cancer Institute 2010. Available from: http:// seer.cancer.gov/csr/1975-2007/index.html [Last accessed 26 September 2011]
5. Ma PC, Jagadeeswaran R, Jagadeesh S, et al. Functional expression and mutations of c-met and its therapeutic inhibition with SU11274 and small interfering RNA in non-small cell lung cancer. Cancer Res 2005;65:1479-88
6. Cooper CS, Park M, Blair DG, et al. Molecular cloning of a new transforming gene from a chemically transformed human cell line. Nature 1984;311:29-33
7. Maulik G, Kijima T, Ma PC, et al. Modulation of the c-Met/hepatocyte growth factor pathway in small cell lung cancer. Clin Cancer Res 2002;8:620-7
8. Sattler M, Hasina R, Reddy M, et al. The role of the c-met pathway in lung cancer and the potential for targeted therapy. Ther Adv Med Oncol 2011;3:171-84
9. Liu Y. The human hepatocyte growth factor receptor gene: complete structural organizaiton and promoter characterization. Gene 1998;215:159-69
10. Ma PC, Kijima T, Maulik G, et al. c-MET mutational analysis in small cell lung cancer: Novel juxtamembrane domain mutations regulating cytoskeletal functions. Cancer Res 2003;63:6272-81
11. Kim ES, Salgia R. MET pathway as a therapeutic target. J Thorac Oncol 2009;4:444-7
12. Zhang YW, Vande Woude GF. HGF/ SF-met signaling in the control of branching morphogenesis and invasion. J Cell Biochem 2003;88:408-17
13. Comoglio PM. Pathway specificity for met signaling. Nat Cell Biol 2001;3:E161-2
14. Nakamura T, Nawa K, Ichihara A, et al. Purification and subunit structure of hepatocyte growth factor from rat platelets. FEBS Lett 1987;224:311-16
15. Basilico C, Arnesano A, Galluzzo M, et al. A high affinity hepatocyte growth factor-binding site in the immunolobulin-like region of met. J Biol Chem 2008;283:21267-77
16. Stamos J, Lazarus RA, Yao X, et al. Crystal structure of the HGF beta-chain in complex with the sema domain of the met receptor. EMBO J 2004;23:2325-35
17. Bladt F, Riethmacher D, Isenmann S, et al. Essential role for the c-met receptor in the migration of myogenic precursor cells into the limb bud. Nature 1995;376:768-71
18. Peruzzi B, Bottaro DP. Targeting the c-met signaling pathway in cancer. Clin Cancer Res 2006;12:3657-60
19. Jeffers M, Rong S, Vande Woude GF. Hepatocyte growth factor/scatter factor-met signaling in tumorigenicity and invasion/metastasis. J Mol Med 1996;74:505-13
20. Comoglio PM, Giordano S, Trusolino L. Drug development of MET inhibitors: targeting oncogene addiction and expedience. Nat Rev Drug 2008;7:504-16
21. Scott A, Salgia R. Biomarkers in lung cancer: from early detection to novel therapeutics and decision making. Biomarker Med 2008;2:577-86
22. Abounader R, Raganathan S, Lal B, et al. Reversion of human glioblastoma malignancy by U1 small nuclear RNA/ ribozyme targeting of scatter factor/ hepatocyte growth factor and c-met expression. J Natl Cancer Inst 1999;91:1548-56
23. Stella MC, Comoglio PM. HGF: a multifunctional growth factor controlling cell scattering. Int J Biochem Cell Biol 1999;31:1357-62
24. Rosen EM, Lamszus K, Laterra J, et al. HGF/SF in angiogenesis. Ciba Found Symp 1997;212:215-29
25. Dong G, Chen Z, Li Z, et al. Hepatocyte growth Factor/Scatter factor-induced activation of MEK and PI3K signal pathways contributes to expression of proangiogenic cytokines interleukin-8 and vascular endothelial growth factor in head and neck squamous cell carcinoma. Cancer Res 2001;61:5911-18
26. Burgess T, Coxon A, Meyer S, et al. Fully human monoclonal antibodies to hepatocyte growth factor with therapeutic potential against hepatocyte growth factor/c-met dependent human tumors. Cancer Res 2006;66:1721-9
27. Rosen PJ, Sweeny CJ, Park DJ, et al. A Phase Ib study of AMG 102 in combination with bevacizumab or motesanib in patients with advanced solid tumors. Clin Cancer Res 2010;16:2677-87
28. Wen PY, Schiff D, Cloughesy TF, et al. A phase II study evaluating the efficacy and safety of AMG102 (rilotumumab) in patients with recurrent glioblastoma. Neuro-Oncol 2011;13:437-46
29. Kim KJ, Whang L, Su Y, et al. Systemic anti-hepatocyte growth factor monoclonal antibody therapy induces the regression of intracranial glioma xenografts. Clin Cancer Res 2006;12:1292-8
30. Stabile LP, Rothstein ME, Keohavong P, et al. Therapeutic targeting of human hepatocyte growth factor with a neutralizing monoclonal antibody reduces lung tumorigenesis. Mol Cancer Ther 2008;7:1913-22
31. Millennium Pharmaceuticals, Inc. Phase I Study of TAK-701 in Adult Patients With Advanced Nonhematological Malignancies. ClinicalTrials.gov NCT00831896. Available from: http://clinicaltrials.gov/ ct2/show/NCT00831896? term=NCT00831896&rank=1 [Last accessed 27 September 2011]
32. Prat M, Crepaldi T, Pennacchietti S, et al. Agonistic monoclonal antibodies against the met receptor dissect the biological responses to HGF. J Cell Sci 1998;111:237-47
33. Petrelli A, Circosta P, Granziero L, et al. Ab-induced ectodomain shedding mediates hepatocyte growth factor receptor down-regulation and hampers biological activity. PNAS 2006;103:5090-5
34. Pacchiana G, Chirlaco C, Stella MC, et al. Monovalency unleashes the full therapeutic potential of the DN-30 anti-met antibody. J Biol Chem 2010;285:36149-57
35. Merchant M, Zheng Z, Romero M, et al. One-armed 5D5 (OA5D5) is a potent humanized HGF-blocking anti-c-Met monovalent antibody that inhibits HGF-dependent activity in vitro and demonstrates anti-tumor efficacy in vivo [LB-372]. In 98th AACR Annual Meeting; 14 - 17 April 2007; Los Angeles, CA
36. Xiang H, Reyes A, Merchant M, et al. Supporting MetMab entry into the clinic with nonclinical pharmacokinetic and pharmacodynamic information. In 20th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics; 21 - 24 October 2008; Geneva, Switzerland
37. Bender B, Xiang H, Reyes AE, et al. Translational pharmacokinetic, pharmacodynamic modeling and simulation analysis of MetMab. In 20th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics; 21 - 24 October 2008; Geneva, Switzerland
38. Moss RA, Bothos JG, Patel PH, et al. Final results from the Phase I study of MetMab, a monovalent antagonist antibody to the receptor Met, dosed as a single agent and in combination with bevacizumab in patients with advanced solid tumor malignancies. In AACR 102nd meeting; 5 April 2011; Orlando, Florida; Abstract MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling
39. Ebert M, Yokoyama M, Friess H, et al. Coexpression of the c-met proto-oncogene and hepatocyte growth factor in human pancreatic cancer. Cancer Res 1994;54:5775-8
40. Jin H, Yang R, Zheng Z, et al. MetMab, the one-armed 5D5 anti-c-met antibody, inhibits orthotopic pancreatic tumor growth and improves survival. Cancer Res 2008;68:4360-8
41. Zucali PA, Ruiz MG, Giovannetti E, et al. Role of cMET expression in non-small-cell lung patients treated with EGFR tyrosine kinase inhibitors. Ann Oncol 2008;19:1605-12
42. Engelman JA, Zejnullahu K, Mitsudomi T, et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2007;316:1039-43
43. Spigel DR, Ervin TJ, Ramlau R, et al. Randomized multicenter double-blind placebo controlled Phase II study evaluating Metmab, anantibody to met receptor, in combination with erlotinib, in patients with advanced non-smallcell lung cancer. In 35th ESMO Conference; 8 - 12 October 2010; Milan, Italy. Ann Oncol 2010;21(Suppl 8):viii7
44. Genentech. A Study of the Safety and Pharmacology of MetMAb (PRO143966), a Monovalent Antagonist Antibody to the Receptor C-Met, Administered Intravenously in Patients With Locally Advanced or Metastatic Solid Tumors. ClinicalTrials.gov NCT01068977. Available from: http://clinicaltrials. gov/ct2/show/NCT01068977? term=NCT01068977&rank=1 [Last accessed 27 September 2011]
45. Genentech. A Study of MetMAb Administered to Patients With Advanced Non-Small Cell Lung Cancer, in Combination With Tarceva (Erlotinib). ClinicalTrials. gov NCT00854308. Available from: http://clinicaltrials.gov/ct2/ show/NCT00854308? term=NCT00854308&rank=1 [Last accessed 27 September 2011]
46. Genentech. A Study Evaluating the Safety and Efficacy of MetMAb in Combination With Paclitaxel and Bevacizumab in Patients With Metastatic, Triple-Negative Breast Cancer. ClinicalTrials.gov NCT01186991. Available from: http://clinicaltrials.gov/ ct2/show/NCT01186991? term=NCT01186991&rank=1 [Last accessed 27 September 2011]